lunedì, 26 luglio 2021
Medinews
8 Settembre 2017

FDA Places Holds on Several Durvalumab Combination Trials

September 7, 2017 – The FDA has placed clinical holds on multiple trials in Celgene’s FUSION program, which is exploring regimens combining the PD-L1 inhibitor durvalumab with immunomodulatory and chemotherapy agents across several hematologic malignancies. The agency has stopped 1 trial and put partial holds on 5 others due to safety concerns that arose in studies evaluating the PD-1 inhibitor pembrolizumab in combination with immunomodulatory agents … (leggi tutto)

TORNA INDIETRO